A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)

Trial Profile

A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 19 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
    • 19 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2020.
    • 11 Apr 2018 According to a Bellicum Pharmaceuticals media release, status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top